SynthesisWorld journal of surgical oncology2026
CD56 negativity is associated with worse survival outcomes in patients with multiple myeloma: a meta-analysis.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prognostic value of cluster of differentiation 56 (CD56) in patients with multiple myeloma (MM) is controversial. This meta-analysis aimed to investigate the association of CD56 with overall survival (OS) and progression-free survival (PFS) in patients with MM.
methodsStudies reporting the association of CD56 with survival outcomes in patients with MM were included. Hazard ratio (HR) values with 95% confidence intervals (CIs) were gathered for pooled analysis.
resultsTwenty-two studies with 2791 patients were included. CD56 negativity was associated with worse OS [HR (95% CI): 2.04 (1.57, 2.65), p < 0.001] and PFS [HR (95% CI): 1.43 (1.23, 1.65), p < 0.001] in patients with MM. Subgroup analyses stratified by regions and CD56 cutoff values were performed. CD56 negativity was associated with shorter OS in studies conducted in Asian countries, studies using ≤ 20% for the cutoff value, and studies using other cutoff values (all p < 0.01). In studies conducted in regions other than Asia, CD56 was not associated with OS. Additionally, CD56 negativity was associated with worse PFS, regardless of region and CD56 cutoff value (all p < 0.05). No publication bias was found, and the pooled analysis was robust.
conclusionCD56 negativity serves as a potential biomarker for predicting worse survival outcomes in patients with MM, especially in Asians, which could improve personalized treatment for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.